Intranasal coadministration of a diazepam prodrug with a converting enzyme results in rapid absorption of diazepam in rats

Davin Rautiola, Patricia D. Maglalang, Narsihmulu Cheryala, Kathryn M. Nelson, Gunda I. Georg, Jared M. Fine, Aleta L. Svitak, Katherine A. Faltesek, Leah R. Hanson, Usha Mishra, Lisa D. Coles, James C. Cloyd, Ronald A. Siegel

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Intranasal administration is an attractive route for systemic delivery of small, lipophilic drugs because they are rapidly absorbed through the nasal mucosa into systemic circulation. However, the low solubility of lipophilic drugs often precludes aqueous nasal spray formulations. A unique approach to circumvent solubility issues involves coadministration of a hydrophilic prodrug with an exogenous converting enzyme. This strategy not only addresses poor solubility but also leads to an increase in the chemical activity gradient driving drug absorption. Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B. Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% 6 6.0%, 112% 6 10%, and 114% 6 7% bioavailability; maximum plasma concentrations 71.5 6 9.3, 388 6 31, and 355 6 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively. Both diazepam and a transient intermediate were absorbed. Enzyme kinetics incorporated into a physiologically based pharmacokinetic model enabled estimation of the first-order absorption rate constants: 0.0689 6 0.0080 minutes21 for diazepam and 0.122 6 0.022 minutes21 for the intermediate. Our results demonstrate that diazepam, which is practically insoluble, can be delivered intranasally with rapid and complete absorption by coadministering avizafone with aminopeptidase B. Furthermore, even faster rates of absorption might be attained simply by increasing the enzyme concentration, potentially supplanting intravenous diazepam or lorazepam or intramuscular midazolam in the treatment of seizure emergencies.

Original languageEnglish (US)
Pages (from-to)796-805
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume370
Issue number3
DOIs
StatePublished - Jan 1 2019

    Fingerprint

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Cite this